Trial · NCT01593241
Therapy De-escalation in Seminoma Stage IIA/B
NCT01593241, Phase 2, Terminated, Swiss Cancer Institute
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Therapy De-escalation in Seminoma Stage IIA/B. Trials, record NCT01593241. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT01593241
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Therapy De-escalation in Seminoma Stage IIA/B
- NCT number
- NCT01593241
- Status
- Terminated
- Phases
- Phase 2
- Enrollment
- 120 participants, actual
- Lead sponsor
- Swiss Cancer Institute
- Conditions
- Seminoma
- Interventions
- Carboplatin, Involved node RT
- First posted
- 2012-05-08
- Last updated
- 2025-02-13
- Other registries' IDs
- eudract:2011-005840-87
Source ClinicalTrials.gov
Registered outcomes10
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Progression free survival (PFS) | at 3 years | PFS is defined as the time from registration until one of the following events occurs: * PD or relapse, defined as progression according to the modified trial-specific version of RECIST 1.1 or a rising level of the tumor marker beta-hCG over the ULN (value must be confirmed by a second measurement). Presence of non-seminoma germ cell tumor has to be excluded in the latter case. * Death from any cause. |
| Secondary | Adverse events (AEs) temporarily associated with the trial treatment | at 3 years | AEs are collected from inclusion until 30 days after the end of treatment |
| Secondary | Late AEs | at the latest at 20 years | AEs will be collected from 30 days after the end of treatment until the end of the follow-up phase |
| Secondary | Incidence of secondary malignancies | at the latest at 20 years | |
| Secondary | Response rate | at 3 years | |
| Secondary | Time to progression (TTP) | at the latest at 20 years | from registration until documented progressive disease, relapse or death due to tumor. |
| Secondary | Overall survival (OS) | at the latest at 20 years. | from registration to the date of death from any cause |
| Secondary | Seminoma specific survival | at the latest at 20 years | from registration to the date of death due to seminoma |
| Secondary | PFS | at the latest at 20 years | from registration to the date of failure of PFS |
| Secondary | Localization of progression | at the latest at 20 years | from first localization where recurrent tumor disease is detected |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers1
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as |
|---|---|
| 36228644 | DERIVED |
Source PubMed
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT01593241
GET https://conductscience.org/api/trials/v1/NCT01593241/registered